Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГНЦ социальной и судебной психиатрии им. В.П.Сербского, Москва
Список исп. литературыСкрыть список 1. Аведисова А.С., Бородин В.И., Чахава В.О. Акинетон или Циклодол? Научно обоснованный выбор. Рос. психиатр. журн. 1998; 6: 4–7. 2. Левин О.С., Шиндряева Н.Н., Аникина М.А. Лекарственный паркинсонизм. Журн. неврол. и психиатр. им. С.С.Корсакова. 2012; 8: 69–74. 3. Малин Д.И., Козырев В.В., Равилов Р.С. Экстрапирамидные побочные эффекты нейролептиков: классификация и современные способы лечения. Психиатр. и психофармакотер. 2001; 3 (6): 12–21. 4. Морозов П.В. Возвращение Акинетона (краткий обзор). Психиатр. и психофармакотер. 2011; 2: 56–8. 5. American Psychiatric Association (APA). Tardive dyskinesia: a task force report of the American Psychiatric Association. Amer Psychiatric Pub 1992. 6. Ananth JV, Horodesky J, Lehmann HE, Ban TA. Effect of withdrawal of antiparkinsonian medication on chronically hospitalized psychiatric patients. Laval Med 1970; 41: 934–8. 7. Arana G. An overview of side effects caused by typical antipsychotics. J Clin Psychiat 2000; 61 (Suppl. 8): 5–11. 8. Avissar S, Schreiber G. Muscarinic receptor subclassification and G-proteins: signify-cance for lithium action in affective disorders and for the treatment of extrapyramidal side effects of neuroleptics. Biolog Psychiat 1989; 26: 113–30. 9. Brown JH. Atropine, scopolamine, and related antimuscarinic drugs. Goodman and Gilman’s. The pharmacological basis of therapeutics. 8th ed. A.Gilman, T.Rall, A.Nies et al. NY, Pergamon 1990; p. 150–65. 10. Delay J, Deniker P. Trente-huit cas de psychoses traitrées par la cure prolongée et continue de 4560 RP. Léme Congrès des Alién, et Neurol de Langue Française, Luxembourg, 21–27 juillet 1952. (Thirty-eight cases of psychoses treated with a long and continued course of 4560 RP. The Congress of the French Language for Alienists and Neurologists, Luxembourg, 21–27 July 1952.) Paris, Masson et Cie 1952; p. 503–13. 11. Delay J, Deniker P, Harl JM. (Therapeutic method derived from hiberno-therapy in excitation and agitation states) Ann Med Psycholog Paris 1952; 110: 267–73. 12. Doshay LJ, Constable K, Zier A. Five year follow-up of treatment with trihexyphenidyl (Artane): outcome in four hundred and eleven cases of paralysis agitans. JAMA 1954; 154: 1334–6. 13. Barnes TR. Neuromuscular effects of neuroleptics: akathisia. J.Kane, J.Lieberman. Adverse effects of psychotropic drugs. The Guilford Press. NY 1992; p. 201–17. 14. Carlsson A. Pharmacological properties of presynaptic dopamine receptor agonists. Psychopharmacol (Suppl.) 1985; 2: 31–8. 15. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiat 2004; 161: 414–25. 16. Double DB, Warren GC, Evans M et al. Efficacy of maintenance use of anticholinergic agents. Acta Psychiat Scand 1993; 88: 381–4. 17. Eltze M, Figala V. Affinity and selectivity of biperiden enantiomers for muscarinic receptor subtypes. Eur J Pharmacol 1988; 158: 11–9. 18. Gerlach J, Lublin H, Peacock L. Extrapyramidal symptoms during long-term treatment with antipsychotics: special focus on clozapine and D1- and D2-dopamine antagonists. Neuropsychopharmacol 1996; 14 (Suppl. 3): s35–9. 19. Gershon S, Olariu J. A new psychotomimetic: its antagonism by tetrahydroaminacrin and its comparison with LSD, mescaline, and sernyl. J Neuropsychiat 1960; 1: 283–92. 20. Glazer WM. Expected incidence of tardive dyskinesia associated with atypical antipsychotics. J Clin Psychiat 2000; 61 (Suppl. 4): 21–6. 21. Glazer WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiat 2000; 61 (Suppl. 4): 15–20. 22. Haase HJ, Janssen PA. The action of neuroleptic drugs. Chicago, IL. Year Book Medical 1965. 23. Hansen TE, Casey DE, Hoffman WF. Neuroleptic intolerance. Schizophr Bull 1997; 23: 567–82. 24. Hippius H. The history of clozapine. Psychopharmacol Berl 1999; 99 (Suppl.): s3–5. 25. Itil TM, Keskiner A, Holden JM. The use of LSD and ditran in the treatment of therapy-resistant schizophrenics. Diseases Nervous System 1969; 30: 93–103. 26. Jellinek T, Gardos G, Cole JO. Adverse effects of antiparkinson drug withdrawal. Am J Psychiat 1981; 138: 1567–71. 27. Jeste DV, Caligiuri MP. Tardive dyskinesia. Schizophr Bull 1993; 19: 303–15. 28. Johnstone EC, Crow TJ, Frith CD, Owens DG. Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychological Med 1983; 13: 513–27. 29. Johnstone EC, Crow TJ, Frith CD, Owens DG. The northwick park «functional» psychosis study: diagnosis and treatment response. Lancet 1988; 2: 119–25. 30. Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988; 8 (Suppl. 4): s52–6. 31. Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiat 2004; (65 Suppl. 9): 16–20. 32. Kane JM, Fleischhacker WW, Hansen L et al. Akathisia: an updated review focusing on second-generation antipsychotics. J Clin Psychiat 2009; 70: 627–43. 33. Kapur S, Zipursky RB, Remington G et al. 5HT2- and D2-receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiat 1998; 155: 921–8. 34. Krauss JK, Yianni J, Loher TJ, Aziz TZ. Deep brain stimulation for dystonia. Clin Neurophysiol 2004; 21 (1): 18–30. 35. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581–9. 36. Leucht S, Corves C, Arbter D et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31–41. 37. Lieberman JA, Saltz BL, Johns CA et al. The effects of clozapine on tardive dyskinesia. Br J Psychiat 1991; 158: 503–10. 38. Manos N, Gkiouzepas J, Tzotzaras T, Tzanetoglou A. Gradual withdrawal of antiparkinson medication in chronic schizophrenics: any better than the abrupt? J Nervous Ment Disease 1981; 169: 659–61. 39. McClelland HA, Blessed G, Bhate S et al. The withdrawal of antiparkinsonian drugs in schizophrenia patients. Br J Psychiat 1974; 124: 151–9. 40. Miller del D, Caroff SN, Davis SM et al. Clinical antipsychotic trials of intervention effectiveness (CATIE) Investigators. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiat 2008; 193: 279–88. 41. Quinn J, Meagher D, Murphy P et al. Vulnerability to involuntary movements over a lifetime trajectory of schizophrenia approaches 100%, in association with executive (frontal) dysfunction. Schizophr Res 2001; 49 (1–2): 79–87. 42. Rashkis HA, Smarr ER. Protection against reserpine-induced «parkinsonism» (clinical note). Am J Psychiat 1957; 113: 1116. 43. Remington G, Kapur S. Neuroleptic-induced extrapyramidal symptoms and the role of combined serotonin/dopamine antagonism. J Clin Psychiat Monogr 1996; 14 (1):14–24. 44. Rifkin A, Quitkin F, Klein D. Akinesia: a poorly recognized drug-induced extra-pyramidal behavioral disorder. Arch Gen Psychiat 1975; 32: 672–4. 45. Schonecker M. Paroxysmal dyskinesia as the effect of megaphen. Nervenarzt 1957; 20; 28 (12): 550–3. 46. Sigwald J, Bouttier D, Raymondeaud C, Piot C. 4 cases of facio-bucco-linguo masticatory dyskinesis of prolonged development following treatment with neuroleptics. Rev Neurol Paris 1959; 100: 751–5. 47. Sigwald J, Boutter D, Courvoisier S. Neurological complications of neuroleptic medication. Rev Neurol Paris 1959; 100: 553–95. 48. Singh MM, Kay SR. Therapeutic antagonism between anticholinergic anti-parkinsonism agents and neuroleptics in schizophrenia: implications for a neuropharmacological model. Neuropsychobiol 1979; 5: 74–86. 49. Singh MM, Kay SR, Opler LA. Anticholinergic-neuroleptic antagonism in terms of positive and negative symptoms in schizophrenia: implications for psychobiological typing. Psycholog Med 1987; 17: 39–48. 50. Stanilla JK, Simpson GM. Drugs to treat extrapyramidal side effects. A.Schatzberg, C.Nemeroff. The american psychiatric textbook of psychopharmacology. 4th ed. Am Psychiat Publish Arlington 2009; p. 669–96. 51. Stein G, Wilkinson G. Seminars in General Adult Psychiatry. 2nd ed. The Royal College Psychiatrists. London 2007. 52. Syvalähti EK, Lauren L, Markannen J, Kunelius R. Interaction of psychotropic drugs with brain muscarinic cholinoceptors: similarities of biperiden and pirenzipine in receptor binding properties. Pharmacol Toxicol 1987; 60: 66–9. 53. Tandon R, Mann NA, Eisner WH, Coppard N. Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients. Psychiat Res 1990; 31 (3): 235–41. 54. Taylor AE, Lang AE, Saint-Cyr JA et al. Cognitive processes in idiopathic dystonia treated with high-dose anticholinergic therapy: implications for treatment strategies. Clin Neuropharmacol 1991; 14: 62–77. 55. Thaker GK, Nguyen JA, Strauss ME et al. Clonazepam treatment of tardive dyskinesia: a practical GABA mimetic strategy. Am J Psychiat 1990; 147 (4): 445–51. 56. Timberlake WH, Schwab RS, England AC. Biperiden (Akineton) in parkinsonism. Arch Neurol 1961; 5: 560–4. 57. Ungvari GS, Chiu HF, Lam LC et al. Gradual withdrawal of long-term anticholinergic antiparkinson medication in Chinese patients with chronic schizophrenia. J Clin Psychopharmacol 1999; 19: 141–8. 58. Uhrbrand L, Faurbye A. Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy. Psychopharmacol 1960; 1: 408–18. 59. Waddington JL, O’Callaghan E, Buckley P et al. Tardive dyskinesia in schizophrenia. Relationship to minor physical anomalies, frontal lobe dysfunction and cerebral structure on magnetic resonance imaging. Br J Psychiat 1995; 167 (1): 41–4.